Chondrosarcoma (Adult)

1. Clinical Overview

Summary

Chondrosarcoma is a malignant bone tumour producing cartilaginous matrix and represents the second most common primary bone malignancy after osteosarcoma, accounting for approximately 20% of primary bone malignancies. [1] It is distinguished by being the most common primary bone sarcoma in adults over 40 years, with peak incidence between 40-70 years, contrasting sharply with osteosarcoma (adolescents) and Ewing sarcoma (children/young adults). [2]

The hallmark radiological feature is "popcorn" or "ring and arc" calcification representing the characteristic chondroid matrix on plain radiographs. [3] The tumour demonstrates a predilection for the axial skeleton, particularly the pelvis (25%), proximal femur, and proximal humerus, though it can occur in any bone. [1]

Critical to management: Chondrosarcoma is notoriously resistant to conventional chemotherapy and radiotherapy due to its hypovascular cartilaginous matrix, poor drug penetration, and low proliferative index. [4] Surgical excision with adequate margins remains the ONLY curative treatment for conventional chondrosarcoma. The extent of surgery—ranging from intralesional curettage with adjuvants for grade I lesions to wide en-bloc resection for higher grades—is determined primarily by histological grade. [5]

Prognosis is heavily dependent on histological grade (I-III), with grade I tumours exhibiting excellent 10-year survival (> 90%), while grade III and dedifferentiated variants carry significantly poorer prognoses (30-40% 10-year survival). [6] The most important prognostic factors are surgical margin adequacy and histological grade.

Clinical Pearls

Surgery is the ONLY Cure: Conventional chondrosarcoma is resistant to chemotherapy and radiotherapy. Adequate surgical margins are paramount—positive margins lead to local recurrence in 25-50% of cases. [5]

"Popcorn Calcification": The radiological buzzword representing cartilaginous matrix. Also described as "ring and arc" or "flocculent" calcification. High T2 signal on MRI reflects the high water content of hyaline cartilage.

Adult Bone Tumour: Unlike osteosarcoma (peak 10-25 years) and Ewing sarcoma (peak 5-20 years), chondrosarcoma predominantly affects older adults (40-70 years). This age distribution is a key diagnostic clue. [2]

Pelvis is Common (and Challenging): The pelvis is the most frequent site (25% of cases), and pelvic chondrosarcomas are notoriously difficult to resect with adequate margins due to anatomical constraints, leading to higher local recurrence rates. [7]

Pain Differentiates Malignancy: Pain—particularly night pain—in a cartilaginous lesion is the most important clinical feature distinguishing chondrosarcoma from benign enchondroma. Painless lesions are almost always benign. [8]

---

2. Epidemiology

Demographics

Anatomical Distribution

Exam Detail: High-Yield Exam Point: The anatomical distribution directly contrasts with osteosarcoma (metaphyses of long bones around knee: distal femur, proximal tibia) and Ewing sarcoma (diaphysis of long bones, flat bones). This distinction is frequently tested in FRCS(Tr&Orth) and oncology examinations.

Risk Factors and Precursor Lesions

Benign Precursor Lesions

Warning Signs of Malignant Transformation

1. New Pain: Onset of pain in previously asymptomatic lesion
2. Growth After Skeletal Maturity: Increase in size after age 30-40 years
3. Increasing Endosteal Scalloping: Progressive cortical thinning from within
4. Soft Tissue Mass: Extension beyond cortex
5. Periosteal Reaction: New bone formation (uncommon in enchondroma)

Clinical Pearl: Ollier/Maffucci Surveillance: Patients with multiple enchondromatosis require lifelong surveillance. Any lesion becoming painful or showing growth warrants urgent investigation with MRI and consideration for biopsy. The proximal/axial lesions carry higher malignant potential than distal extremity lesions.

---

3. Pathophysiology

Molecular Pathogenesis

Recent advances have identified key molecular drivers of chondrosarcoma:

IDH1 and IDH2 Mutations

Isocitrate Dehydrogenase (IDH) mutations are found in approximately 50-70% of conventional chondrosarcomas, particularly grade I-II tumours. [12]

• IDH1 mutation (R132): Most common, present in ~50-60% of cases
• IDH2 mutation (R172): Present in ~10-15% of cases
• Mechanism: Mutant IDH produces 2-hydroxyglutarate (2-HG), an oncometabolite that causes:
  • Hypermethylation of DNA and histones
  • Blockade of cellular differentiation
  • Chondrocyte maturation arrest
  • Accumulation of immature cartilage cells

Clinical Significance: IDH mutations are associated with:

• Lower grade tumours (I-II)
• Better prognosis
• Potential therapeutic target (IDH inhibitors under investigation)
• Diagnostic marker (can help distinguish from enchondroma in ambiguous cases)

Exam Detail: Molecular Examination Focus: IDH mutations represent a major recent advance in chondrosarcoma biology and are increasingly tested in postgraduate examinations (FRCS, Oncology MCQs). Contrast with osteosarcoma (TP53, RB1 mutations) and Ewing sarcoma (EWSR1-FLI1 fusion).

Other Molecular Alterations

Classification Systems

1. By Origin

2. Histological Grading (WHO Classification)

The most important prognostic factor. Based on:

• Cellularity
• Nuclear atypia
• Mitotic activity
• Myxoid change

Critical Clinical Note: Distinguishing grade I chondrosarcoma from enchondroma can be extremely difficult histologically. Clinical and radiological correlation is mandatory. Pain is the key discriminator. [8]

3. Special Subtypes

Exam Detail: Viva Scenario - Dedifferentiated Chondrosarcoma:

"A 60-year-old with a known pelvic enchondroma for 10 years presents with new severe pain and rapid enlargement. X-ray shows the previous popcorn calcification but now with an aggressive lytic area and soft tissue mass. What is your concern?"

Model Answer: "This presentation is highly suspicious for dedifferentiated chondrosarcoma—transformation of the pre-existing low-grade cartilaginous lesion into a high-grade non-cartilaginous sarcoma. The radiological clue is the 'biphasic' appearance: retained popcorn calcification representing the low-grade component, plus an aggressive lytic/destructive area representing the high-grade dedifferentiated component. This carries a very poor prognosis with 5-year survival around 20-30%. Management requires urgent staging with MRI and CT thorax, biopsy to confirm, and consideration for wide en-bloc resection if feasible. Unlike conventional chondrosarcoma, chemotherapy may be considered for the high-grade component, though efficacy remains limited."

Metastatic Spread

Patterns of Metastasis

Metastatic Risk by Grade:

• Grade I: less than 5% metastatic rate
• Grade II: 10-15% metastatic rate
• Grade III: 30-50% metastatic rate [6]

Timeline: Chondrosarcoma can metastasize late (even 5-10 years post-treatment), necessitating prolonged surveillance.

---

4. Clinical Presentation

Symptoms

Signs on Examination

Clinical Pearl: **"Pain in the Night"

• The Bone Tumour Red Flag**:

Any patient presenting with bone pain that:

1. Wakes them from sleep
2. Not relieved by rest
3. Progressive over weeks-months
4. Not explained by trauma

...requires immediate investigation with plain radiographs and onwards referral if suspicious features present. This applies across all primary bone malignancies (osteosarcoma, Ewing, chondrosarcoma, myeloma).

Presentation by Anatomical Site

---

5. Differential Diagnosis

Primary Differential Diagnoses

Critical Distinction: Enchondroma vs. Chondrosarcoma

This is the MOST DIFFICULT and MOST CLINICALLY IMPORTANT differential in cartilaginous tumours. [8]

Exam Detail: FRCS Viva Question - Enchondroma vs Chondrosarcoma:

"A 50-year-old presents with a proximal humeral lesion showing popcorn calcification and endosteal scalloping of 50% cortical thickness. Biopsy shows a low-grade cartilaginous lesion. The pathologist cannot definitively distinguish enchondroma from grade I chondrosarcoma. How do you proceed?"

Model Answer:

"This is the classic diagnostic dilemma in cartilaginous tumours. Clinical and radiological correlation is essential—the histology alone cannot always distinguish enchondroma from grade I chondrosarcoma.

Key clinical question: Is it painful?

• If painful (especially night pain): Presume chondrosarcoma → Treat with excision (intralesional curettage + adjuvants for grade I)
• If painless: More likely enchondroma → Consider observation with serial imaging

Radiological features favouring chondrosarcoma:

• Endosteal scalloping > 2/3 cortical thickness (50% is borderline)
• Size > 5 cm
• Proximal/axial location (proximal humerus is intermediate risk)
• Soft tissue mass

In this case, the age (50), location (proximal humerus), and scalloping are concerning, but the 50% scalloping is not definitive. If the patient has pain, I would recommend surgical excision. If painless, I would discuss at sarcoma MDT and consider close surveillance with repeat MRI in 3-6 months to assess for progression. Any increase in size or development of symptoms warrants excision."

---

6. Investigations

Initial Investigations

Plain Radiographs (AP and Lateral)

First-line investigation. Key features:

Clinical Pearl: Radiological Grading Clues:

• Grade I: Well-defined, endosteal scalloping less than 2/3, popcorn calcification, NO soft tissue mass
• Grade II-III: Ill-defined margins, endosteal scalloping > 2/3, cortical destruction, soft tissue extension
• Dedifferentiated: Biphasic appearance—retained calcification + new aggressive lytic area

MRI (Magnetic Resonance Imaging)

Gold standard for local staging and surgical planning. [19]

MRI is essential for:

• Defining intramedullary extent
• Assessing soft tissue extension
• Planning surgical margins
• Identifying neurovascular involvement
• Differentiating from other tumours

Limitation: Cannot reliably distinguish enchondroma from grade I chondrosarcoma. Clinical pain is the discriminator.

CT Scan

Biopsy

Essential for definitive diagnosis and grading, but requires careful technique and expert interpretation.

Biopsy Challenges:

1. Grading Difficulty: Grade I chondrosarcoma can be histologically indistinguishable from enchondroma. Clinical/radiological correlation essential. [8]
2. Sampling Error: Chondrosarcomas are heterogeneous. Biopsy may miss higher-grade areas. Multiple cores from different regions recommended.
3. Dedifferentiation: Biopsy must sample any lytic/non-calcified areas to detect high-grade dedifferentiated component.

Exam Detail: Biopsy Principles in Bone Sarcoma (High-Yield for FRCS):

1. Biopsy tract contamination: Biopsy tract must be excised en-bloc with definitive resection
2. Performed at sarcoma centre: Ideally by operating surgeon, along planned surgical approach
3. Avoid neurovascular structures: Do not violate multiple compartments
4. Haemostasis crucial: Haematoma spreads tumour cells
5. Longitudinal incision: Along limb axis, can be incorporated into definitive surgical scar

Common exam scenario: "What are the principles of biopsy in suspected bone sarcoma?" → Answer should cover the above points.

Laboratory Investigations

Chondrosarcoma typically does NOT cause abnormal blood tests (unlike Ewing sarcoma with elevated inflammatory markers or myeloma with paraprotein).

Staging Investigations

Staging System: AJCC/UICC TNM for Bone Sarcoma

---

7. Management

Management Algorithm

         SUSPECTED CHONDROSARCOMA
         (Adult > 40, Painful lesion, Popcorn calcification, Endosteal scalloping)
                       ↓
         INITIAL WORKUP
         - Plain X-rays (AP/Lateral)
         - MRI of lesion (local extent, soft tissue involvement)
         - CT Thorax (pulmonary metastases)
                       ↓
         REFERRAL TO SARCOMA CENTRE
         (All suspected bone tumours MUST be referred to specialist centre)
                       ↓
         MULTIDISCIPLINARY TEAM (MDT) DISCUSSION
         - Orthopaedic Oncologist
         - Radiologist (MSK)
         - Histopathologist
         - Oncologist
         - Clinical Nurse Specialist
                       ↓
         BIOPSY (Core Needle or Open Incisional)
         - Image-guided, performed at sarcoma centre
         - Along planned surgical approach
         - Multiple cores for adequate sampling
                       ↓
         HISTOLOGICAL GRADE CONFIRMED
         ┌────────────────┴────────────────┐
      GRADE I                        GRADE II/III or DEDIFFERENTIATED
      (Low-grade)                    (Intermediate/High-grade)
         ↓                                  ↓
      INTRALESIONAL                    WIDE LOCAL EXCISION
      CURETTAGE                        (En-bloc resection, wide margins)
      + Local Adjuvants                - Tumour + cuff of normal tissue
      - Argon beam coagulation         - Margin: 2-3 cm circumferential
      - Phenol                         - Frozen section intraoperatively
      - Polymethylmethacrylate         - Sacrifice of expendable structures
      - Liquid nitrogen                  if necessary
      - Indications:                      ↓
        • Small (less than 5cm)              RECONSTRUCTION
        • Contained                 Options depend on defect:
        • Accessible                1. ENDOPROSTHESIS (Mega-prosthesis)
        • Expendable bone              - Proximal femur, proximal humerus
          (e.g., proximal fibula)   2. ALLOGRAFT (Structural bone graft)
                                    3. ALLOGRAFT-PROSTHESIS COMPOSITE
                                    4. AUTOGRAFT (Vascularized fibula)
                                    5. AMPUTATION
                                       - If neurovascular involvement
                                       - Inadequate margins impossible
                                       - Pathological fracture with contamination
                       ↓
         ADJUVANT THERAPY CONSIDERATION
         ┌──────────────────────────────────────────────────────────┐
         │  CONVENTIONAL CHONDROSARCOMA (Grade I-III):             │
         │  ❌ Chemotherapy = INEFFECTIVE                          │
         │  ❌ Radiotherapy = INEFFECTIVE                          │
         │  (Chondrosarcoma is notoriously resistant due to:)      │
         │  - Hypovascular cartilaginous matrix                    │
         │  - Poor drug penetration                                │
         │  - Low proliferative index [4]                          │
         │                                                          │
         │  EXCEPTIONS:                                             │
         │  ✅ Mesenchymal Chondrosarcoma:                         │
         │     - May respond to chemotherapy                       │
         │     - Doxorubicin + Ifosfamide protocols [15]           │
         │  ✅ Dedifferentiated Chondrosarcoma:                    │
         │     - Consider chemotherapy for high-grade component    │
         │     - Limited efficacy, poor prognosis                  │
         │  ✅ Proton Beam Radiotherapy:                           │
         │     - For unresectable axial skeleton tumours           │
         │     - Skull base, spine (where surgery impossible)      │
         │     - Better than conventional RT [21]                  │
         └──────────────────────────────────────────────────────────┘
                       ↓
         FOLLOW-UP SURVEILLANCE
         - Clinical examination: 3-monthly Year 1-2, 6-monthly Year 3-5, annually thereafter
         - CT Thorax: 6-monthly for 5 years (metastasis detection)
         - MRI of primary site: 6-12 monthly (local recurrence detection)
         - Duration: Lifelong (late recurrence/metastases can occur 10+ years post-treatment)

Surgical Management Principles

1. Surgical Margins

The most important prognostic factor for local recurrence. [5]

2. Surgical Options by Grade

Grade I Chondrosarcoma

Extended Intralesional Curettage + Local Adjuvants

Appropriate for:

• Small lesions (less than 5 cm)
• Contained within bone
• Accessible surgical site
• Expendable bone (e.g., proximal fibula)

Technique:

1. Wide cortical window
2. Thorough curettage of all cartilaginous tissue
3. High-speed burr to remove 1-2 mm of cavity wall
4. Local adjuvants (to kill residual microscopic disease):
   • Argon beam coagulation (thermal)
   • Phenol application (chemical cauterization)
   • Liquid nitrogen (cryotherapy, −196°C)
5. Cavity filling with polymethylmethacrylate (PMMA) cement (thermal effect during polymerization, structural support)

Outcomes: Local recurrence 5-15% with adjuvants (vs 25-50% without). [22]

Grade II-III Chondrosarcoma

Wide En-Bloc Resection

Principles:

1. Wide margins: 2-3 cm circumferential cuff of normal tissue
2. En-bloc resection: Tumour and surrounding tissue removed as single specimen, intact pseudocapsule
3. No violation of tumour during dissection
4. Sacrifice of expendable structures: Nerves (if not major motor), muscles (if adequate function remains)
5. Intraoperative frozen section: Assess margin adequacy
6. Biopsy tract excision: Entire biopsy tract removed en-bloc

Reconstruction Options:

3. Amputation

Indications:

• Neurovascular bundle involvement (major nerves: sciatic, femoral, brachial plexus)
• Extensive soft tissue involvement precluding adequate margins
• Pathological fracture with contamination of multiple compartments
• Failed limb salvage (recurrence, infection)
• Patient preference (some prefer reliable amputation over complex reconstruction)

Level of Amputation: Proximal to tumour with adequate margin (typically one joint above).

Outcomes: Despite advances in limb salvage, amputation rates remain 10-20% for pelvic/proximal femur chondrosarcomas. [7]

Exam Detail: Viva Scenario - Surgical Decision Making:

"A 55-year-old has a grade II chondrosarcoma of the proximal femur with extension to the lesser trochanter but sparing the sciatic and femoral neurovascular bundle. What are your surgical options and considerations?"

Model Answer:

"This is a challenging case requiring careful surgical planning. The lesion is grade II, so wide local excision is mandatory—intralesional curettage is inadequate.

Surgical Options:

1. Wide resection + Endoprosthetic reconstruction (Preferred):

   • Resect proximal femur en-bloc with 2-3 cm margins
   • Reconstruct with modular proximal femoral replacement (mega-prosthesis)
   • Reattach abductors to prosthesis (critical for function)
   • Advantages: Immediate weight-bearing, good pain relief, reasonable function (80-90% for ADLs)
   • Complications: Dislocation (10-15%), infection (5-10%), aseptic loosening (10-year rate ~10%)

2. Allograft-Prosthesis Composite:

   • Structural allograft for bone stock, prosthesis for joint
   • Allows soft tissue (abductor) reattachment to bone
   • Higher non-union, fracture, infection risk than prosthesis alone

3. Amputation (Hip disarticulation):

   • If neurovascular involvement, inadequate margins impossible, or patient preference
   • Reliable oncological outcome, but significant functional impact

My Approach: Given neurovascular bundle sparing, I would proceed with wide resection and endoprosthetic reconstruction. Pre-operative planning with MRI to define exact tumour extent, plan osteotomy levels, and ensure 2-3 cm margins achievable. Intraoperative frozen section to confirm negative margins. Close liaison with sarcoma MDT and patient counselling regarding complication risks."

Role of Chemotherapy and Radiotherapy

Chemotherapy

Conventional Chondrosarcoma (Grade I-III): NO ROLE [4]

Why chondrosarcoma resists chemotherapy:

1. Hypovascular cartilaginous matrix: Poor blood supply → poor drug delivery
2. Low proliferative index: Chondrocytes divide slowly → chemotherapy (which targets dividing cells) ineffective
3. Multidrug resistance proteins: High expression of P-glycoprotein (MDR1)
4. Extracellular matrix barrier: Dense cartilage matrix impedes drug penetration

Evidence: Multiple studies have shown no survival benefit from adjuvant or neoadjuvant chemotherapy in conventional chondrosarcoma. [4]

Exceptions:

Radiotherapy

Conventional Chondrosarcoma: Generally INEFFECTIVE [4]

Reasons for radioresistance:

1. Low mitotic rate
2. Hypoxic cartilage matrix
3. Efficient DNA repair mechanisms

Conventional Radiotherapy: No role in adjuvant setting for resectable disease.

Exceptions:

Proton Beam Radiotherapy: Available at specialist centres (UK: Manchester, London). Higher dose to tumour, lower dose to surrounding normal tissues. Particularly valuable for skull base chordomas and chondrosarcomas. [21]

Follow-Up and Surveillance

Rationale: Chondrosarcoma can recur locally and metastasize late (even 10+ years post-treatment). Prolonged surveillance essential. [6]

What to monitor:

• Local recurrence: Pain, palpable mass, MRI shows new/enlarging lesion at resection site
• Pulmonary metastases: Asymptomatic (detected on CT), or cough, dyspnoea, haemoptysis if large
• Functional outcome: ROM, pain, activities of daily living
• Prosthesis complications: Dislocation, loosening, infection (if endoprosthesis)

Management of Recurrence:

• Local recurrence: Re-resection with wider margins if feasible, or amputation
• Pulmonary metastases: Metastasectomy if limited number (less than 5 nodules), unilateral, grade I-II primary. Can be curative in selected cases. [23]

---

8. Complications

Disease-Related Complications

Surgery-Related Complications

Functional Complications

Rehabilitation: Essential post-operatively. Physiotherapy for ROM, strengthening, gait training. Occupational therapy for ADLs.

---

9. Prognosis and Outcomes

Survival by Histological Grade

[6,14]

Prognostic Factors

Exam Detail: Most Important Prognostic Factors (High-Yield):

1. Histological Grade (I vs II vs III)
2. Surgical Margin (R0 vs R1/R2)

These two factors dominate prognosis more than any other variables. A grade I tumour with positive margins has higher recurrence than grade II with negative margins. [5,6]

Location-Specific Outcomes

Metastatic Disease

Natural History:

• Site: Lungs > 90% of metastases [6]
• Timing: Can occur late (5-10 years after primary treatment)
• Survival: Median survival with metastatic disease: 12-24 months (untreated)

Pulmonary Metastasectomy: For selected patients with:

• Limited number of metastases (less than 5)
• Unilateral or sequential bilateral
• Completely resectable
• Good performance status
• Grade I-II primary

Outcomes: 5-year survival post-metastasectomy: 40-50% (highly selected patients). [23]

Quality of Life

Functional Outcomes: Most patients (70-80%) achieve good functional outcomes with modern limb salvage techniques, though not reaching pre-morbid function.

Limb Salvage vs Amputation: Studies show similar survival but better perceived quality of life with limb salvage (though functional outcomes may be equivalent when measured objectively).

---

10. Prevention and Screening

Primary Prevention

No established primary prevention for sporadic chondrosarcoma.

Secondary Prevention (For At-Risk Individuals)

Patient Education for Enchondroma/Ollier/HME:

• Report any new pain in known lesions
• Report any growth/enlargement
• Avoid trauma (pathological fracture complicates diagnosis and management)

---

11. Evidence and Guidelines

Key Guidelines

Landmark Studies

Current Research Directions

---

12. Patient and Layperson Explanation

What is Chondrosarcoma?

Chondrosarcoma is a cancer of the cartilage cells inside your bones. Cartilage is the smooth, rubbery tissue that normally covers the ends of bones in joints (like your knees or shoulders). In chondrosarcoma, abnormal cartilage cells grow inside the bone, forming a tumour.

It is the second most common type of bone cancer (after osteosarcoma), but unlike most bone cancers that affect children and teenagers, chondrosarcoma mainly affects adults aged 40-70 years. It grows slowly compared to other cancers, which is why symptoms often develop gradually over many months or even years.

Where does it occur?

The most common places are:

• Pelvis (hip bone)
• Upper thigh bone (femur)
• Shoulder (upper arm bone - humerus)
• Ribs

It is unusual in the hands, feet, or lower leg.

What are the symptoms?

The most common symptom is pain:

• Deep, aching pain in the bone
• Gets worse at night (this is an important warning sign for any bone cancer)
• Not relieved by rest or painkillers
• Gradually worsens over weeks to months

You might also notice:

• A lump or swelling over the bone
• Reduced movement of a nearby joint (e.g., stiff shoulder or hip)
• Rarely, a sudden break (fracture) in the bone if the tumour has weakened it

How is it diagnosed?

1. X-rays: Show a characteristic "popcorn" appearance (speckled calcification)
2. MRI scan: Shows the exact size and spread of the tumour
3. CT scan of the chest: Checks if the cancer has spread to the lungs (the most common place)
4. Biopsy: A small sample of the tumour is taken (with a needle or small operation) and examined under a microscope to confirm the diagnosis and determine the "grade" (how aggressive it is)

What are the grades?

Chondrosarcoma is divided into three grades:

• Grade I (Low-grade): Slow-growing, rarely spreads, excellent outlook
• Grade II (Intermediate): Moderate growth rate, can sometimes spread
• Grade III (High-grade): Fast-growing, higher risk of spreading to the lungs

The grade is the most important factor in deciding treatment and predicting outcomes.

How is it treated?

Surgery is the only cure for chondrosarcoma.

Unlike many other cancers, chondrosarcoma does NOT respond well to chemotherapy or radiotherapy. This is because:

• The cartilage matrix has poor blood supply, so chemotherapy drugs cannot reach the tumour effectively
• The cancer cells grow slowly, and chemotherapy works best on fast-dividing cells

For Grade I (Low-grade):

• Curettage (scraping out the tumour from inside the bone)
• Use of chemicals, heat, or cold to kill any remaining cancer cells
• Filling the hole with bone cement or bone graft

For Grade II-III (Intermediate/High-grade):

• Wide excision (removing the tumour with a margin of normal tissue around it)
• This often requires removing a section of bone
• Reconstruction with a metal replacement (prosthesis), bone graft from a donor (allograft), or your own bone
• In rare cases where the tumour is very large or involves major nerves/blood vessels, amputation may be necessary

What happens after surgery?

• Physiotherapy: To regain strength and movement
• Regular check-ups: Every 3-6 months for the first 5 years, then annually
• CT scans of the chest: Every 6 months to check for spread to the lungs
• MRI scans of the original site: To check the cancer hasn't come back

What is the outlook?

The outlook depends on the grade:

• Grade I: More than 90% of people are alive and cancer-free 10 years after treatment
• Grade II: About 60-80% are alive at 10 years
• Grade III: About 30-50% are alive at 10 years

Important: Even low-grade chondrosarcoma can come back many years later, so long-term follow-up is essential.

Can it spread?

If chondrosarcoma spreads, it almost always goes to the lungs. This is more likely with higher-grade tumours (Grade II-III). If caught early, lung metastases can sometimes be surgically removed, which can still lead to long-term survival in some people.

What if I have a benign cartilage tumour (enchondroma)?

Many people have small benign cartilage tumours called enchondromas (especially in the fingers and hands) that never cause problems. The key difference is:

• Enchondromas are painless
• Chondrosarcomas are painful (especially at night)

If you have a known enchondroma and it starts to hurt or grow, see your doctor immediately, as this could be a sign it is turning into chondrosarcoma.

Questions to ask your doctor

1. What grade is my chondrosarcoma?
2. Can the tumour be removed completely with surgery?
3. Will I need a metal replacement or bone graft?
4. What will my movement be like after surgery?
5. How often will I need scans?
6. What are the chances it will come back?

Support and Resources

• Bone Cancer Research Trust: www.bcrt.org.uk
• Sarcoma UK: www.sarcoma.org.uk
• Macmillan Cancer Support: www.macmillan.org.uk

---

13. References

Primary Sources

1. Gerrand C, Athanasou N, Brennan B, et al. UK guidelines for the management of bone sarcomas. Clin Sarcoma Res. 2016;6:7. PMID: 27094006. DOI: 10.1186/s13569-016-0047-1.

2. Giuffrida AY, Burgueno JE, Koniaris LG, et al. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 2009;91(5):1063-1072. PMID: 19411454. DOI: 10.2106/JBJS.H.00416.

3. Murphey MD, Walker EA, Wilson AJ, et al. From the archives of the AFIP: imaging of primary chondrosarcoma: radiologic-pathologic correlation. Radiographics. 2003;23(5):1245-1278. PMID: 12975513. DOI: 10.1148/rg.235035134.

4. Lee FY, Mankin HJ, Fonti G, et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am. 1999;81(3):326-338. PMID: 10199270. DOI: 10.2106/00004623-199903000-00004.

5. Andreou D, Gilg MM, Gosheger G, et al. Metastatic potential of grade I chondrosarcoma of bone: results of a multi-institutional study. Ann Surg Oncol. 2016;23(Suppl 5):120. DOI: 10.1245/s10434-015-4848-9.

6. Fiorenza F, Abudu A, Grimer RJ, et al. Risk factors for survival and local control in chondrosarcoma of bone. J Bone Joint Surg Br. 2002;84(1):93-99. PMID: 11837840. DOI: 10.1302/0301-620x.84b1.11942.

7. Pring ME, Weber KL, Unni KK, Sim FH. Chondrosarcoma of the pelvis. A review of sixty-four cases. J Bone Joint Surg Am. 2001;83(11):1630-1642. PMID: 11701784. DOI: 10.2106/00004623-200111000-00002.

8. Skeletal Lesions Interobserver Correlation among Expert Diagnosticians (SLICED) Study Group. Reliability of histopathologic and radiologic grading of cartilaginous neoplasms in long bones. J Bone Joint Surg Am. 2007;89(10):2113-2123. PMID: 17908885. DOI: 10.2106/JBJS.F.01530.

9. Liu J, Hudkins PG, Swee RG, Unni KK. Bone sarcomas associated with Ollier's disease. Cancer. 1987;59(7):1376-1385. PMID: 3815300.

10. Verdegaal SH, Bovée JV, Pansuriya TC, et al. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist. 2011;16(12):1771-1779. PMID: 22147001. DOI: 10.1634/theoncologist.2011-0200.

11. Wicklund CL, Pauli RM, Johnston D, Hecht JT. Natural history study of hereditary multiple exostoses. Am J Med Genet. 1995;55(1):43-46. PMID: 7702095. DOI: 10.1002/ajmg.1320550113.

12. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224(3):334-343. PMID: 21598255. DOI: 10.1002/path.2913.

13. Bovée JV, Cleton-Jansen AM, Rosenberg C, et al. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. J Pathol. 1999;189(4):454-462. PMID: 10629543.

14. Grimer RJ, Gosheger G, Taminiau A, et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. Eur J Cancer. 2007;43(14):2060-2065. PMID: 17720521. DOI: 10.1016/j.ejca.2007.06.016.

15. Shakked RJ, Geller DS, Gorlick R, Dorfman HD. Mesenchymal chondrosarcoma: clinicopathologic study of 20 cases. Arch Pathol Lab Med. 2012;136(1):61-68. PMID: 22208489. DOI: 10.5858/arpa.2011-0131-OA.

16. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523-532. PMID: 24345772. DOI: 10.1016/j.ctrv.2013.11.006.

17. Gaspar N, Hawkins DS, Dirksen U, et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol. 2015;33(27):3036-3046. PMID: 26304877. DOI: 10.1200/JCO.2014.59.5256.

18. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s-6249s. PMID: 17062708. DOI: 10.1158/1078-0432.CCR-06-0931.

19. Geirnaerdt MJ, Bloem JL, Eulderink F, et al. Cartilaginous tumors: correlation of gadolinium-enhanced MR imaging and histopathologic findings. Radiology. 1993;186(3):813-817. PMID: 8430192. DOI: 10.1148/radiology.186.3.8430192.

20. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am. 1982;64(8):1121-1127. PMID: 7130225.

21. DeLaney TF, Liebsch NJ, Pedlow FX, et al. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol. 2014;110(2):115-122. PMID: 24752878. DOI: 10.1002/jso.23617.

22. Bauer HC, Brosjö O, Kreicbergs A, Lindholm J. Low risk of recurrence of enchondroma and low-grade chondrosarcoma in extremities. 80 patients followed for 2-25 years. Acta Orthop Scand. 1995;66(3):283-288. PMID: 7604717. DOI: 10.3109/17453679508995538.

23. Briccoli A, Rocca M, Salone M, et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer. 2005;104(8):1721-1725. PMID: 16116597. DOI: 10.1002/cncr.21361.

24. Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv79-iv95. PMID: 30285218. DOI: 10.1093/annonc/mdy310.

25. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral [NG12]. Published June 2015. Updated October 2021. Available at: https://www.nice.org.uk/guidance/ng12

26. Tap WD, Villalobos VM, Cote GM, et al. Phase I study of the mutant IDH1 inhibitor ivosidenib: safety and clinical activity in patients with advanced chondrosarcoma. J Clin Oncol. 2020;38(15):1693-1701. PMID: 32167863. DOI: 10.1200/JCO.19.02492.

---

14. Examination Focus

Common Exam Questions

Written Exam (MCQ/SBA)

1. Classic Presentation: "A 55-year-old man presents with deep pelvic pain worse at night for 6 months. X-ray shows a lytic lesion with 'popcorn' calcification and endosteal scalloping of > 2/3 cortical thickness. What is the most likely diagnosis?"

   • Answer: Chondrosarcoma

2. Treatment: "What is the primary treatment for conventional chondrosarcoma?"

   • Answer: Surgical excision with wide margins (Chemotherapy and radiotherapy are ineffective)

3. Prognosis: "Which factor is the MOST important prognostic indicator in chondrosarcoma?"

   • Answer: Histological grade (I vs II vs III)

4. Differential Diagnosis: "What is the KEY clinical feature distinguishing chondrosarcoma from enchondroma?"

   • Answer: Pain (Chondrosarcoma is painful, especially at night; enchondroma is painless)

5. Molecular Genetics: "Which genetic mutation is most commonly associated with low-grade chondrosarcoma?"

   • Answer: IDH1 mutation (R132)

Clinical Exam (Viva/OSCE)

Scenario 1: Radiograph Interpretation

"You are shown an X-ray of a proximal femur with a lytic lesion containing 'popcorn' calcification, endosteal scalloping, and a soft tissue mass."

Expected Discussion Points:

• Describe findings: "Lytic lesion with chondroid matrix calcification ('popcorn'), endosteal scalloping > 2/3 cortex, soft tissue extension"
• Differential diagnosis: Chondrosarcoma (most likely), enchondroma (unlikely given soft tissue mass), dedifferentiated chondrosarcoma
• Grade estimation: Soft tissue mass suggests grade II-III or dedifferentiated
• Next investigations: MRI (local extent), CT thorax (staging), biopsy (confirm diagnosis and grade)
• Management: Referral to sarcoma centre, MDT discussion, likely wide excision + endoprosthetic reconstruction

Scenario 2: Surgical Planning

"A 60-year-old has a grade II chondrosarcoma of the proximal humerus. Discuss your surgical approach."

Model Answer Structure:

1. Goals: Wide excision (R0 resection), preserve neurovascular bundle, restore function
2. Approach: Deltopectoral or extended anterior approach
3. Resection: Proximal humerus excision, osteotomy distal to tumour with 2-3 cm margin, protect brachial plexus/axillary vessels
4. Frozen section: Confirm negative margins intraoperatively
5. Reconstruction: Endoprosthesis vs allograft-prosthesis composite. Reattach rotator cuff to prosthesis if possible.
6. Expected function: Pain relief excellent, ROM 40-60% of normal, can perform ADLs
7. Complications: Infection, dislocation, prosthesis loosening, nerve injury

Scenario 3: Enchondroma vs Chondrosarcoma

"A 45-year-old has a painless lesion in the proximal humerus with popcorn calcification and 40% endosteal scalloping. Biopsy shows low-grade cartilaginous lesion. Pathologist cannot distinguish enchondroma from grade I chondrosarcoma. What do you do?"

Model Answer:

• Acknowledge diagnostic difficulty: "Histology alone cannot always distinguish enchondroma from grade I chondrosarcoma"
• Clinical correlation is key: Is it painful?
  • Painful → Presume malignant → Excise
  • Painless → Likely benign → Observe with serial imaging
• Radiological features:
  • 40% scalloping is intermediate (> 2/3 = concerning, less than 1/3 = benign)
  • Location (proximal humerus) is concerning (hands/feet more reassuring)
• Management options:
  1. If painful: Intralesional curettage + adjuvants (grade I protocol)
  2. If painless: Close surveillance with MRI every 3-6 months, excise if any growth or new pain
• MDT discussion essential

High-Yield Viva Points

1. Chondrosarcoma is chemo/radiotherapy resistant → Surgery is the ONLY cure
2. Pain differentiates benign (enchondroma) from malignant (chondrosarcoma)
3. Histological grade is the most important prognostic factor (I vs II vs III)
4. Surgical margins are critical → R0 resection required for cure
5. Pelvis is the most common site, but hardest to resect with adequate margins
6. Dedifferentiated chondrosarcoma = low-grade cartilage + high-grade non-cartilaginous component → very poor prognosis
7. IDH1/IDH2 mutations in ~70% of conventional chondrosarcoma → diagnostic marker, potential therapeutic target
8. Metastases go to lungs > 90% of the time, can be late (5-10 years)
9. Endosteal scalloping > 2/3 cortical thickness = malignancy until proven otherwise
10. Ollier/Maffucci = multiple enchondromatosis → 25-50% malignant transformation risk → lifelong surveillance

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and follow local protocols.